Header Ads

πŸ“ˆπŸ“ˆ Bullish Penny Stocks $1-$10 for 7.11.2019 πŸ’΅πŸ’΅ - #stockstowatch #pennystocks

What Is a Penny Stock: A penny stock refers to a small company's stock that typically trades for less than $5 per share. Although some penny stocks trade on large exchanges such as the New York Stock Exchange (NYSE), most penny stocks trade via over the counter (OTC) transactions. Transactions take place through the electronic OTC Bulletin Board (OTCBB) or through the privately-owned Pink Sheets. There is no trading floor for OTC transactions, and the quotations are also all done electronically.

The desire to make a quick killing in the stock market draws many inexperienced investors to trade in penny stocks. Unfortunately, this also means many people lose their money in the blink of an eye.
Why would anyone take on this type of risk? As the saying goes, “the higher the risk, the higher the potential returns.” If invested in the right companies, penny stocks can provide enormous returns. So if you’re comfortable with the risk versus return trade-off, and understand that you could lose your money, penny stocks could play a role in your portfolio.

Jonny Red's Penny Stock Trade Thoughts Below:

The below listed Penny Stock Tickers are all those that meet the criteria of the scanner.  These are tickers that need to be watched and analyzed at Market Open to see if they will continue their Northern Momentum. I have posted a few of the charts for my favorite ones.

All of these tickers close today with 3 consecutive Green closes. I typically always look for penny's stock plays that have 2 to 3 consecutive GREEN days, and at least 800k+ in volume.

Transparent Trader Bullish Penny Stocks $1-$10 Range: http://tos.mx/izmLDK

Transparent Traders Low Float Scanner for Penny Stocks http://tos.mx/OKvQSM

Borroow Some of My Stock Screeners: Click Here

See all Bullish Tickers below, but My Top Ticker Symbols are: TV - KDMN - XOG - ACRX


TV - Grupo Televisa, S.A.B. operates as a media company in the Spanish-speaking world. The company operates through four segments: Content, Sky, Cable, and Other Businesses. The Content segment produces television programming and broadcasts Channels 2, 4, 5, and 9; sells advertising time on programs; provides Internet services; and produces television programming and broadcasting for local television stations in Mexico and the United States. It also offers programming services for cable and pay-per-view television companies in Mexico, other countries in Latin America, the United States, and Europe; and licenses and syndicates television programming. The Sky segment offers direct-to-home broadcast satellite pay television services comprising program, installation, and equipment rental services to subscribers in Mexico, Central America, and the Dominican Republic; and national advertising sales. The Cable segment operates cable multiple system and telecommunication facilities. It provides basic and premium television subscription, pay-per-view, installation, Internet subscription, and telephone services, as well as local and national advertising sales; and data and long-distance services solutions to carriers and other telecommunications service providers through its fiber-optic network. The Other Businesses segment is involved in sports and show business promotion, soccer, feature film production and distribution, gaming, radio, publishing, and publishing distribution businesses. Grupo Televisa, S.A.B. was founded in 1990 and is based in Mexico City, Mexico.


KDMN - Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.


XOG - Extraction Oil & Gas, Inc., an independent oil and gas company, focuses on the acquisition, development, and production of oil, natural gas, and natural gas liquid reserves in the Rocky Mountain region, primarily in the Wattenberg Field of the Denver-Julesburg (DJ) Basin of Colorado. The company also engages in the construction and support of midstream assets to gather, process, and produce crude oil and gas. As of December 31, 2018, it had approximately 179,300 net acres of contiguous acreage blocks in the productive areas of the DJ Basin; held approximately 138,100 net acres outside of the Core DJ Basin; had estimated proved reserves of approximately 347.9MMBoe; and had 1,538 gross producing wells. The company was founded in 2012 and is headquartered in Denver, Colorado.


ACRX - AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.



No comments